Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | GNRHR | P30968 | 3/20 | 0.33 |
| ▸ | MLLT1 | Q03111 | 2/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776046 | 0.95 | FAAH (0.35) | RPS6KA2PRMT5WDR77FAAHGNRHR | |
| SCHEMBL16776230 | 0.90 | PRMT5 (0.39) | RPS6KA2PRMT5WDR77FAAHGSK3B | |
| SCHEMBL16776279 | 0.90 | GSK3B (0.38) | RPS6KA2FAAHMLLT1ARGSK3B | |
| SCHEMBL16776240 | 0.89 | WNT1 (0.35) | PRMT5WDR77MLLT1HDAC8GSK3B | |
| SCHEMBL16776188 | 0.89 | ATR (0.42) | RPS6KA2FAAHATRGSK3BDYRK1A | |
| SCHEMBL16776143 | 0.89 | RPS6KA2 (0.39) | RPS6KA2PRMT5WDR77FAAHHDAC8 | |
| SCHEMBL16776050 | 0.85 | PRMT5 (0.38) | RPS6KA2PRMT5WDR77FAAHHDAC8 | |
| SCHEMBL16776244 | 0.85 | ABL1 (0.40) | — | |
| SCHEMBL16776243 | 0.84 | RPS6KA3 (0.39) | RPS6KA2PRMT5WDR77DYRK1A | |
| SCHEMBL16776037 | 0.84 | FGFR4 (0.37) | RPS6KA2FAAHHDAC8GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RPS6KA2 2318/4885PRMT5 209/4885WDR77 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.